VISEN Pharmaceuticals announced a repurchase of 9,200 ordinary shares on 18 May 2026 via on-exchange transactions at prices between HK$22.84 and HK$22.98, averaging HK$22.95 per share. The total consideration amounted to HK$0.21 million.

Following the transaction, VISEN’s issued share capital (excluding treasury shares) declined 0.008 % to 113.92 million shares, while the same number of shares—9,200—has been transferred to treasury stock. The overall issued share count, including treasury shares, remains unchanged at 113.93 million.

The buyback was executed under the share repurchase mandate approved on 27 June 2025, which authorises the company to repurchase up to 11.39 million shares. To date, 9,200 shares—representing 0.08 % of the issued share base as at the mandate date—have been repurchased under this authority.

In accordance with Hong Kong Stock Exchange regulations, VISEN is subject to a moratorium on issuing new shares or selling treasury shares until 17 June 2026.